Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment

Muscle Nerve. 2017 Mar;55(3):E12-E13. doi: 10.1002/mus.25458. Epub 2016 Nov 25.

Authors

Paolo E Alboini¹, Amelia Evoli¹, Valentina Damato¹, Raffaele Iorio¹, Emanuela Bartoccioni²

Affiliations

¹ Institute of Neurology, Largo F. Vito, 1 - 00168, Catholic University, Rome, Italy.
² General Pathology, Catholic University, Rome, Italy.

PMID: 27808416
DOI: 10.1002/mus.25458

No abstract available

Keywords: JAK/STAT; JAK/STAT inhibitors; MuSK; myasthenia gravis; myelofibrosis; ruxolitinib.

Publication types

Case Reports

MeSH terms

Aged
Autoantibodies / immunology
Female
Humans
Myasthenia Gravis / complications
Myasthenia Gravis / immunology
Myasthenia Gravis / physiopathology*
Nitriles
Primary Myelofibrosis / complications
Primary Myelofibrosis / drug therapy*
Pyrazoles / therapeutic use*
Pyrimidines
Receptor Protein-Tyrosine Kinases / immunology
Receptors, Cholinergic / immunology
Remission Induction

Substances

Autoantibodies
Nitriles
Pyrazoles
Pyrimidines
Receptors, Cholinergic
ruxolitinib
MUSK protein, human
Receptor Protein-Tyrosine Kinases